These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. Carr RM; Patnaik MM Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455 [TBL] [Abstract][Full Text] [Related]
24. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174 [TBL] [Abstract][Full Text] [Related]
25. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851 [TBL] [Abstract][Full Text] [Related]
26. TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors. Qu X; Zhang S; Wang S; Wang Y; Li W; Huang Y; Zhao H; Wu X; An C; Guo X; Hale J; Li J; Hillyer CD; Mohandas N; Liu J; Yazdanbakhsh K; Vinchi F; Chen L; Kang Q; An X Blood; 2018 Nov; 132(22):2406-2417. PubMed ID: 30254129 [TBL] [Abstract][Full Text] [Related]
27. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816 [No Abstract] [Full Text] [Related]
28. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood. Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372 [TBL] [Abstract][Full Text] [Related]
29. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis. Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061 [TBL] [Abstract][Full Text] [Related]
30. Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism. Polizio AH; Marino L; Min KD; Yura Y; Rolauer L; Cochran JD; Evans MA; Park E; Doviak H; Miura-Yura E; Good ME; Wolpe AG; Grandoch M; Isakson BE; Walsh K Circ Res; 2024 Oct; 135(9):933-950. PubMed ID: 39234670 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis. Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175 [TBL] [Abstract][Full Text] [Related]
32. [TET2 gene in hematological diseases]. Li S; Wang XQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):836-41. PubMed ID: 24989305 [TBL] [Abstract][Full Text] [Related]
33. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940 [TBL] [Abstract][Full Text] [Related]
37. Clonal Hematopoiesis of Indeterminate Potential With Loss of Lin AE; Bapat AC; Xiao L; Niroula A; Ye J; Wong WJ; Agrawal M; Farady CJ; Boettcher A; Hergott CB; McConkey M; Flores-Bringas P; Shkolnik V; Bick AG; Milan D; Natarajan P; Libby P; Ellinor PT; Ebert BL Circulation; 2024 Apr; 149(18):1419-1434. PubMed ID: 38357791 [TBL] [Abstract][Full Text] [Related]
38. [TET2 as a gatekeeper for hematologic malignancies]. Muto H; Sakata-Yanagimoto M; Chiba S Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875 [TBL] [Abstract][Full Text] [Related]
39. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139 [TBL] [Abstract][Full Text] [Related]
40. Myeloid cell tet methylcytosine dioxygenase 2 does not affect the host response during gram-negative bacterial pneumonia and sepsis. Qin W; Brands X; van 't Veer C; de Vos AF; Scicluna BP; van der Poll T Cytokine; 2022 Jun; 154():155876. PubMed ID: 35405484 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]